SG11201806110QA - Treatment of cancer with combinations of immunoregulatory agents - Google Patents

Treatment of cancer with combinations of immunoregulatory agents

Info

Publication number
SG11201806110QA
SG11201806110QA SG11201806110QA SG11201806110QA SG11201806110QA SG 11201806110Q A SG11201806110Q A SG 11201806110QA SG 11201806110Q A SG11201806110Q A SG 11201806110QA SG 11201806110Q A SG11201806110Q A SG 11201806110QA SG 11201806110Q A SG11201806110Q A SG 11201806110QA
Authority
SG
Singapore
Prior art keywords
california
international
regimen
pct
stanford
Prior art date
Application number
SG11201806110QA
Inventor
Stephen Willingham
Doris Po Yi Ho
Kelly Marie McKenna
Irving L Weissman
Jens-Peter Volkmer
Mark P Chao
Ravindra Majeti
Melissa N Mccracken
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG11201806110QA publication Critical patent/SG11201806110QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/127707 Al 27 July 2017 (27.07.2017) WIPO I PCT 1111111111111101110101011111010111110111011101011101110111111111111111111110111111 International Patent Classification: C07K 16/46 (2006.01) C07K 16/28 (2006.01) International Application Number: PCT/US2017/014375 International Filing Date: 20 January 2017 (20.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/281,571 21 January 2016 (21.01.2016) US 62/301,981 1 March 2016 (01.03.2016) US (71) Applicant: THE BOARD OF TRUSTEES OF THE LE- LAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel, Building 170, 3rd Floor, Main Quad, P.O. Box 20386, Stanford, California 94305- 2038 (US). (72) Inventors: WILLINGHAM, Stephen; 1317 Victoria Ter- race, Sunnyvale, California 94087 (US). HO, Doris Po Yi; 139 MacDonald Avenue, Daly City, California 94014 (US). MCKENNA, Kelly Marie; 4192 Maybell Way, Palo Alto, California 94306 (US). WEISSMAN, Irving L.; 747 Santa Ynez Street, Stanford, California 94305 (US). VOLKMER, Jens-Peter; 12 Coleman Place, Apt. 2, Menlo Park, California 94025 (US). CHAO, Mark P.; 2001 Showers Drive, Mountain View, California 94040 (US). MAJETI, Ravindra; 861 Newell Place, Palo Alto, California 94303 (US). MCCRACKEN, Melissa N.; 910 Rich Avenue, Apt. 7, Mountain View, California 94040 (US). (74) Agent: SHERWOOD, Pamela J.; 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) W O 20 171277 / 07 Al (54) Title: TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS (57) : Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen com- prising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is en- hanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
SG11201806110QA 2016-01-21 2017-01-20 Treatment of cancer with combinations of immunoregulatory agents SG11201806110QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281571P 2016-01-21 2016-01-21
US201662301981P 2016-03-01 2016-03-01
PCT/US2017/014375 WO2017127707A1 (en) 2016-01-21 2017-01-20 Treatment of cancer with combinations of immunoregulatory agents

Publications (1)

Publication Number Publication Date
SG11201806110QA true SG11201806110QA (en) 2018-08-30

Family

ID=59360269

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806110QA SG11201806110QA (en) 2016-01-21 2017-01-20 Treatment of cancer with combinations of immunoregulatory agents

Country Status (9)

Country Link
US (2) US20170210803A1 (en)
EP (2) EP3405499A4 (en)
JP (3) JP7026047B2 (en)
KR (1) KR20180102628A (en)
CN (1) CN109071676A (en)
AU (2) AU2017210224B2 (en)
CA (1) CA3011429A1 (en)
SG (1) SG11201806110QA (en)
WO (1) WO2017127707A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716552B (en) 2016-01-11 2024-05-24 四十七公司 Humanized, mouse or chimeric anti-CD 47 monoclonal antibodies
JP7308191B2 (en) * 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド Anti-CD47 agent-based ovarian cancer therapy
EP4194470A1 (en) * 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
MX2020005463A (en) 2017-12-01 2020-09-07 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer.
WO2019109357A1 (en) * 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 Anti-pd-1/cd47 bispecific antibody and application thereof
CN111699005A (en) 2018-02-12 2020-09-22 四十七公司 Anti-cancer regimens using anti-CD47 antibodies and anti-CD 20 antibodies
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US20210338681A1 (en) * 2018-10-01 2021-11-04 Secura Bio, Inc. Combination therapies
CN109517073A (en) * 2018-11-30 2019-03-26 北京泽勤生物医药有限公司 A kind of fusogenic peptide of targeting therapy on tumor and its application
AU2019409805A1 (en) * 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
WO2020163692A1 (en) * 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
EP3934658A4 (en) * 2019-03-08 2023-03-29 North Carolina State University Bio-responsive antibody complexes for enhanced immunotherapy
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
MX2022006578A (en) 2019-12-17 2022-07-04 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
EP4349868A2 (en) 2010-05-14 2024-04-10 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
KR102081567B1 (en) * 2012-01-25 2020-02-26 디엔에이트릭스, 인코포레이티드 Biomarkers and combination therapies using oncolytic virus and immunomodulation
PT2925782T (en) * 2012-12-03 2020-04-22 Novimmune Sa Anti-cd47 antibodies and methods of use thereof
BR112015013431A2 (en) * 2012-12-12 2017-11-14 Vasculox Inc monoclonal antibodies or antigen-binding fragments thereof, pharmaceutical composition, and uses of monoclonal antibody or antigen-binding fragment thereof
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
EP4186927A1 (en) * 2015-10-21 2023-05-31 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
CN107459578B (en) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 Difunctional fusion protein targeting CD47 and PD-L1

Also Published As

Publication number Publication date
AU2024202900A1 (en) 2024-05-23
WO2017127707A1 (en) 2017-07-27
EP3405499A4 (en) 2020-03-18
CA3011429A1 (en) 2017-07-27
AU2017210224B2 (en) 2024-02-08
US20210230276A1 (en) 2021-07-29
AU2017210224A1 (en) 2018-08-02
JP2019506400A (en) 2019-03-07
JP7026047B2 (en) 2022-02-25
US20170210803A1 (en) 2017-07-27
KR20180102628A (en) 2018-09-17
JP2022033899A (en) 2022-03-02
CN109071676A (en) 2018-12-21
JP2023085370A (en) 2023-06-20
EP4070812A1 (en) 2022-10-12
EP3405499A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
SG11201806110QA (en) Treatment of cancer with combinations of immunoregulatory agents
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804934PA (en) Novel Compounds
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201805645QA (en) Lsd1 inhibitors
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201407200TA (en) Liquid formulation
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201908929VA (en) Synthekine compositions and methods of use
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201909837YA (en) Methods for treating lung disorders
SG11201804671SA (en) Aza-benzimidazole inhibitors of pad4
SG11201804440XA (en) Chemical reprogramming of human glial cells into neurons with small molecule cocktail